In conclusion, tirabrutinib exerted an anti-tumor effect by regulating multiple BTK downstream signaling proteins, such as NF-κB, AKT, and ERK, in ABC-DLBCL. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.